|
1
|
Winawer S, Fletcher R, Rex D, et al:
Colorectal cancer screening and surveillance: clinical guidelines
and rationale - Update based on new evidence. Gastroenterology.
124:544–560. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Loktionov A, O’Neill IK, Silvester KR, et
al: Quantitation of DNA from exfoliated colonocytes isolated from
human stool surface as a novel noninvasive screening test for
colorectal cancer. Clin Cancer Res. 4:337–342. 1998.PubMed/NCBI
|
|
3
|
Davies RJ, Miller R and Coleman N:
Screening for colorectal cancer using stool. Discov Med. 5:175–179.
2005.PubMed/NCBI
|
|
4
|
Lin H, Balic M, Zheng S, Datar R and Cote
RJ: Disseminated and circulating tumor cells: Role in effective
cancer management. Crit Rev Oncol Hematol. 77:1–11. 2011.
View Article : Google Scholar
|
|
5
|
Eyles J, Puaux AL, Wang X, et al: Tumor
cells disseminate early, but immunosurveillance limits metastatic
outgrowth, in a mouse model of melanoma. J Clin Invest.
120:2030–2039. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim MY, Oskarsson T, Acharyya S, et al:
Tumor self-seeding by circulating cancer cells. Cell.
139:1315–1326. 2009. View Article : Google Scholar
|
|
7
|
Sastre J, Maestro ML, Puente J, et al:
Circulating tumor cells in colorectal cancer: correlation with
clinical and pathological variables. Ann Oncol. 19:935–938. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Iinuma H, Watanabe T, Mimori K, et al:
Clinical significance of circulating tumor cells, including cancer
stem-like cells, in peripheral blood for recurrence and prognosis
in patients with Dukes’ stage B and C colorectal cancer. J Clin
Oncol. 29:1547–1555. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wong SC, Chan CM, Ma BB, et al: Clinical
significance of cytokeratin 20-positive circulating tumor cells
detected by a refined immunomagnetic enrichment assay in colorectal
cancer patients. Clin Cancer Res. 15:1005–1012. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chiappini F: Circulating tumor cells
measurements in hepatocellular carcinoma. Int J Hepatol.
2012:6848022012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Allan AL and Keeney M: Circulating tumor
cell analysis: technical and statistical considerations for
application to the clinic. J Oncol. 2010:4262182010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Attard G and de Bono JS: Utilizing
circulating tumor cells: challenges and pitfalls. Curr Opin Genet
Dev. 21:50–58. 2011. View Article : Google Scholar
|
|
13
|
Lianidou ES and Markou A: Circulating
tumor cells in breast cancer: detection systems, molecular
characterization, and future challenges. Clin Chem. 57:1242–1255.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun YF, Yang XR, Zhou J, et al:
Circulating tumor cells: advances in detection methods, biological
issues, and clinical relevance. J Cancer Res Clin Oncol.
137:1151–1173. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Alunni-Fabbroni M and Sandri MT:
Circulating tumour cells in clinical practice: Methods of detection
and possible characterization. Methods. 50:289–297. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Königsberg R, Obermayr E, Bises G, et al:
Detection of EpCAM positive and negative circulating tumor cells in
metastatic breast cancer patients. Acta Oncol. 50:700–710. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Panteleakou Z, Lembessis P, Sourla A, et
al: Detection of circulating tumor cells in prostate cancer
patients: methodological pitfalls and clinical relevance. Mol Med.
15:101–114. 2009. View Article : Google Scholar
|
|
18
|
Yu M, Stott S, Toner M, Maheswaran S and
Haber DA: Circulating tumor cells: approaches to isolation and
characterization. J Cell Biol. 192:373–382. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Parkinson DR, Dracopoli N, Petty BG, et
al: Considerations in the development of circulating tumor cell
technology for clinical use. J Transl Med. 10:1382012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hu Y, Fan L, Zheng J, et al: Detection of
circulating tumor cells in breast cancer patients utilizing
multiparameter flow cytometry and assessment of the prognosis of
patients in different CTCs levels. Cytometry A. 77:213–219. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Allan AL, Vantyghem SA, Tuck AB, et al:
Detection and quantification of circulating tumor cells in mouse
models of human breast cancer using immunomagnetic enrichment and
multiparameter flow cytometry. Cytometry A. 65:4–14. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Takao M and Takeda K: Enumeration,
characterization, and collection of intact circulating tumor cells
by cross contamination-free flow cytometry. Cytometry A.
79:107–117. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
van de Stolpe A, Pantel K, Sleijfer S,
Terstappen LW and den Toonder JM: Circulating tumor cell isolation
and diagnostics: toward routine clinical use. Cancer Res.
71:5955–5960. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Paterlini-Brechot P and Benali NL:
Circulating tumor cells (CTC) detection: clinical impact and future
directions. Cancer Lett. 253:180–204. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Armstrong AJ, Marengo MS, Oltean S, et al:
Circulating tumor cells from patients with advanced prostate and
breast cancer display both epithelial and mesenchymal markers. Mol
Cancer Res. 9:997–1007. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bonnomet A, Brysse A, Tachsidis A, et al:
Epithelial-to-mesenchymal transitions and circulating tumor cells.
J Mammary Gland Biol Neoplasia. 15:261–273. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Aktas B, Tewes M, Fehm T, et al: Stem cell
and epithelial-mesenchymal transition markers are frequently
overexpressed in circulating tumor cells of metastatic breast
cancer patients. Breast Cancer Res. 11:R462009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Barrière G, Riouallon A, Renaudie J,
Tartary M and Rigaud M: Mesenchymal and stemness circulating tumor
cells in early breast cancer diagnosis. BMC Cancer. 12:1142012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen CL, Mahalingam D, Osmulski P, et al:
Single-cell analysis of circulating tumor cells identifies
cumulative expression patterns of EMT-related genes in metastatic
prostate cancer. Prostate. 73:813–826. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kallergi G, Papadaki MA, Politaki E, et
al: Epithelial to mesenchymal transition markers expressed in
circulating tumour cells of early and metastatic breast cancer
patients. Breast Cancer Res. 13:R592011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Thiery JP and Lim CT: Tumor dissemination:
an EMT affair. Cancer Cell. 23:272–273. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rhim AD, Mirek ET, Aiello NM, et al: EMT
and dissemination precede pancreatic tumor formation. Cell.
148:349–361. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Burgess DJ: Breast cancer: Circulating and
dynamic EMT. Nat Rev Cancer. 13:1482013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yu M, Bardia A, Wittner BS, et al:
Circulating breast tumor cells exhibit dynamic changes in
epithelial and mesenchymal composition. Science. 339:580–584. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Budd GT: Let me do more than count the
ways: what circulating tumor cells can tell us about the biology of
cancer. Mol Pharm. 6:1307–1310. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pang R, Law WL, Chu AC, et al: A
subpopulation of CD26+ cancer stem cells with metastatic
capacity in human colorectal cancer. Cell Stem Cell. 6:603–615.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Herrlich P, Zöller M, Pals ST and Ponta H:
CD44 splice variants: metastases meet lymphocytes. Immunol Today.
14:395–399. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sun YX, Pedersen EA, Shiozawa Y, et al:
CD26/dipeptidyl peptidase IV regulates prostate cancer metastasis
by degrading SDF-1/CXCL12. Clin Exp Metastasis. 25:765–776. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Galizia G, Orditura M, Ferraraccio F, et
al: The lymph node ratio is a powerful prognostic factor of
node-positive colon cancers undergoing potentially curative
surgery. World J Surg. 33:2704–2713. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chapuis PH, Dent OF, Bokey EL, Newland RC
and Sinclair G: Adverse histopathological findings as a guide to
patient management after curative resection of node-positive
colonic cancer. Br J Surg. 91:349–354. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: the 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sobin LH and Compton CC: TNM seventh
edition: what’s new, what’s changed: communication from the
International Union Against Cancer and the American Joint Committee
on Cancer. Cancer. 116:5336–5339. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Galizia G, Gemei M, Del Vecchio L, et al:
Combined CD133/CD44 expression as a prognostic indicator of
disease-free survival in patients with colorectal cancer. Arch
Surg. 147:18–24. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gemei M, Mirabelli P, Di Noto R, et al:
CD66c is a novel marker for colorectal cancer stem cell isolation,
and its silencing halts tumor growth in vivo. Cancer. 119:729–738.
2013. View Article : Google Scholar
|
|
45
|
Galizia G, Gemei M, Orditura M, et al:
Postoperative detection of circulating tumor cells predicts tumor
recurrence in colorectal cancer patients. J Gastrointest Surgery.
17:1809–1818. 2013. View Article : Google Scholar
|
|
46
|
Hayes DF and Smerage JB: Circulating tumor
cells. Prog Mol Biol Transl Sci. 95:95–112. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wicha MS and Hayes DF: Circulating tumor
cells: not all detected cells are bad and not all bad cells are
detected. J Clin Oncol. 29:1508–1511. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Elsaba TM, Martinez-Pomares L, Robins AR,
et al: The stem cell marker CD133 associates with enhanced colony
formation and cell motility in colorectal cancer. PLoS One.
5:e107142010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bourseau-Guilmain E, Griveau A, Benoit JP
and Garcion E: The importance of the stem cell marker
prominin-1/CD133 in the uptake of transferrin and in iron
metabolism in human colon cancer Caco-2 cells. PLoS One.
6:e255152011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Du L, Wang H, He L, et al: CD44 is of
functional importance for colorectal cancer stem cells. Clin Cancer
Res. 14:6751–6760. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Chantrain CF, Feron O, Marbaix E and
DeClerck YA: Bone marrow microenvironment and tumor progression.
Cancer Microenviron. 1:23–35. 2008. View Article : Google Scholar
|
|
52
|
Janni W, Vogl FD, Wiedswang G, et al:
Persistence of disseminated tumor cells in the bone marrow of
breast cancer patients predicts increased risk for relapse - a
European pooled analysis. Clin Cancer Res. 17:2967–2976. 2011.
View Article : Google Scholar : PubMed/NCBI
|
